Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glecaprevir/Pibrentasvir in HCV Genotype 5 or 6
NCT02966795Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2017
- Primary completion
- Jun 2018
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 9
01
Overview
Phase 3, open-label trial of glecaprevir in hepatitis C (HCV) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Sustained Virologic Response 12 Weeks Post Treatment. Started Jan 2017; status: completed.
02
Drugs
glecaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02966795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966795.